As it prepares for Phase 3 trials for diabetes treatment, vTv Therapeutics reports $19.2M net loss in FY 2022

High Point biopharmaceutical company vTv Therapeutics is hoping to turn things around under new leadership and with its its lead product – an oral treatment for Type 1 Diabetes – heading into Phase 3 clinical trials.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news